Replies to post #137090 on Biotech Values

[acgood]

Ideally you'd like to get some crizotnib-naive ALK patients exposed to the drug, but that would have to come later in the process.

I would have agreed, but the first SNTA ALK+ HSP90 inhibitor trial is in crizotinib-naive patients rather than failures.